In a recently published study, researchers sought to determine the cost effectiveness of bevacizumab in treating recurrent ovarian cancer from a Canadian public payer perspective.
Ovarian cancer is a leading cause of cancer-related morality, and in Canada, ovarian cancer is estimated to affect approximately 1 in every 71 women. The prognosis for ovarian cancer is poor, and very few therapeutic options are available for women with recurrent ovarian cancer, especially disease that is platinum-resistant.
In a recently published study, researchers sought to determine the cost effectiveness of bevacizumab in treating recurrent ovarian cancer from a Canadian public payer perspective. The investigators compared bevacizumab plus chemotherapy versus chemotherapy alone in patients with platinum-resistant recurrent ovarian cancer based on clinical data from the AURELLIA phase 3 trial.
The study was conducted by evaluating a 3 health-state cohort-based partitioned survival models developed to assess the cost utility of bevacizumab plus chemotherapy versus chemotherapy alone over a 7-year horizon. Researchers reconstructed individual patient data from published Kaplan-Meier curves. Clinical parameters, including progression-free survival and overall survival, were derived from the AURELIA trial. Costs, resource utilization, and utility values from recent Canadian sources were compiled by the study authors and used to populate the model. The results of the study were then presented in incremental cost-utility ratios (ICURs).
In reconstructing the individual patient data, the authors found:
Overall, researchers found that the addition of bevacizumab to a single-agent chemotherapy treatment, although it improved patient outcomes, is unlikely to be cost-effective in this patient population. This result is due to bevacizumab plus chemotherapy not being considered cost-effective at willingness-to-pay thresholds below approximately $200,000 (approximately $155,900 USD) per QALY gained. However, the study’s authors also note that these results provide some preliminary validation for the use of individual patient data-reconstruction techniques in pharmacoeconomic evaluation.
Reference
Ball G, Xie F, Tarride JE. Economic evaluation of bevacizumab for treatment of platinum-resistant recurrent ovarian cancer in Canada. Published online May 29, 2017. Pharmacoeconomics. doi: 10.1007/s41669-017-0030-7.
Global Biosimilar Market Projected to Reach $1.3 Trillion by 2032
April 11th 2024The global biosimilar market is projected to surge from $25.1 billion in 2022 to approximately $1.3 trillion by 2032, with a compound annual growth rate of 17.6%, driven mainly by the increasing prevalence of cancer and the cost-effectiveness of biosimilars, as outlined in a report by Towards Healthcare.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
Study: More Biosimilar Competition Is Not Lowering Patient OOP Costs
March 29th 2024Despite more biosimilars entering the market and generating significant savings for payers and health care systems, these savings are not resulting in lower out-of-pocket (OOP) costs for patients, according to a recent study.
Filgrastim Biosimilars in Europe: 15 Years of Real-World Evidence for Zarxio
March 13th 2024A review looking back at the last 15 years of experience with the first filgrastim biosimilar (Zarxio) provides a detailed overview on how filgrastim biosimilars came to be and the evidence behind why oncologists have come to accept them as standard practice.